DiscoveRx (United States)

Recent papers from DiscoveRx (United States)

1. Abstract 6934: Integrated evaluation of payload-, Fc-, and target-mediated mechanisms of ADCs using streamlined complementary platformsCancer Research · 2026
2. Abstract 5543: Mechanism-driven cell-based assays to screen & characterize bi-specific antibodiesCancer Research · 2026
3. Placemaking-Based Town Development Learning Through Regional CollaborationAIJ Journal of Technology and Design · 2026
4. The Universal Causality Bound (X = 0.15)2026
5. Comprehensive Analysis of Clinically Discontinued Compounds Using an In Vitro Secondary Pharmacology Panel to Predict Potential Safety Risks during Drug DevelopmentACS Pharmacology & Translational Science · 2025
6. De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors2025
7. Impacts of imageability of architecture on brain health: A systematic literature reviewLandscape and Urban Planning · 2024
8. Suite of Biochemical and Cell-Based Assays for the Characterization of Kirsten Rat Sarcoma (KRAS) Inhibitors and DegradersACS Pharmacology & Translational Science · 2024
9. Why We Need More Autistic Health Care Professionals and How to Support ThemAutism in Adulthood · 2024
10. Abstract 89: Comprehensive cell based bioassay approaches for characterization, and clinical development of therapeutic agonistic antibodies for cancer immunotherapy and autoimmune diseasesCancer Research · 2024
11. Lessons in waste management: Deciphering the dual role of Crustacean Rh1 protein in ammonia and CO2 excretionActa Physiologica · 2024
12. Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology modelScientific Reports · 2023
13. Formate overflow drives toxic folate trapping in MTHFD1 inhibited cancer cellsNature Metabolism · 2023
14. Abstract 5688: IND-enabling characterization of ONC206 as the next bitopic antagonist for oncologyCancer Research · 2020
15. The activities of drug inactive ingredients on biological targetsScience · 2020
16. The Kinase Chemogenomic Set (KCGS): An open science resource for kinase vulnerability identification2019
17. Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK)Bioorganic & Medicinal Chemistry Letters · 2019
18. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease ModelsThe Journal of Immunology · 2019
19. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 AntagonismClinical Cancer Research · 2018
20. Advancing nonclinical innovation and safety in pharmaceutical testingDrug Discovery Today · 2018